BR112013008526A2 - inibidores de quinase do tipo polo - Google Patents

inibidores de quinase do tipo polo

Info

Publication number
BR112013008526A2
BR112013008526A2 BR112013008526A BR112013008526A BR112013008526A2 BR 112013008526 A2 BR112013008526 A2 BR 112013008526A2 BR 112013008526 A BR112013008526 A BR 112013008526A BR 112013008526 A BR112013008526 A BR 112013008526A BR 112013008526 A2 BR112013008526 A2 BR 112013008526A2
Authority
BR
Brazil
Prior art keywords
kinase inhibitors
pole type
type kinase
pole
inhibitors
Prior art date
Application number
BR112013008526A
Other languages
English (en)
Inventor
Anh P Troung
Danielle L Aubele
Dean Richard Artis
Jefrey R Neitz
Jennifer Sealy
John P Anderson
Marc Adler
Paul Beroza
Robert A Galemmo
Roy K Hom
Simeon Bowers
Xiaocong Michael Ye
Yong-Liang Zhu
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of BR112013008526A2 publication Critical patent/BR112013008526A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
BR112013008526A 2010-10-08 2011-10-06 inibidores de quinase do tipo polo BR112013008526A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40475810P 2010-10-08 2010-10-08
US201061425560P 2010-12-21 2010-12-21
PCT/US2011/055134 WO2012048129A2 (en) 2010-10-08 2011-10-06 Inhibitors of polo-like kinase

Publications (1)

Publication Number Publication Date
BR112013008526A2 true BR112013008526A2 (pt) 2016-07-12

Family

ID=45928437

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013008526A BR112013008526A2 (pt) 2010-10-08 2011-10-06 inibidores de quinase do tipo polo

Country Status (10)

Country Link
US (1) US20120115848A1 (pt)
EP (1) EP2661268A2 (pt)
JP (1) JP2013539759A (pt)
CN (1) CN103403010A (pt)
AU (1) AU2011311960A1 (pt)
BR (1) BR112013008526A2 (pt)
CA (1) CA2814084A1 (pt)
IL (1) IL225605A0 (pt)
RU (1) RU2014118677A (pt)
WO (1) WO2012048129A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163755B2 (en) * 2009-08-28 2012-04-24 Takeda Pharmaceutical Company Limited Hexahydrooxazinopterine compounds
CN103351310A (zh) * 2013-07-01 2013-10-16 太仓市恒益医药化工原料厂 一种用于肟的制备工艺
CN103819400B (zh) * 2013-09-16 2016-05-04 江西师范大学 一种多组分反应合成具有不对称结构1.4-二氢吡啶及其衍生物的方法
WO2016183071A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
RS65129B1 (sr) 2016-03-28 2024-02-29 Incyte Corp Jedinjenja pirolotriazina kao inhibitori tam
WO2019067594A1 (en) 2017-09-27 2019-04-04 Incyte Corporation SALTS OF PYRROLOTRIAZINE DERIVATIVES USEFUL AS TAM INHIBITORS
CN108084188A (zh) * 2017-12-23 2018-05-29 广东赛博科技有限公司 哌嗪***类化合物、制备方法及其用途
PE20211805A1 (es) 2018-06-29 2021-09-14 Incyte Corp Formulaciones de un inhibidor de axl/mer
CN110511226B (zh) * 2019-09-06 2021-07-09 西南交通大学 化合物或其盐或溶剂合物、其应用和药物组合物
CN117567338A (zh) 2019-10-09 2024-02-20 拜耳公司 作为农药的新的杂芳基***化合物
CN112661620A (zh) * 2019-10-16 2021-04-16 中国石油化工股份有限公司 一种环戊酮的制备方法
CN112661604A (zh) * 2019-10-16 2021-04-16 中国石油化工股份有限公司 基于镍系负载型催化剂的环戊醇的制备方法
CN114671810B (zh) * 2022-03-21 2024-03-22 济南鸿湾生物技术有限公司 一种咪唑苯脲的制备方法
CN116768906B (zh) * 2023-05-29 2024-04-09 遵义医科大学珠海校区 一种三并环化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005079799A1 (en) 2004-02-13 2005-09-01 Glaxo Group Limited 4-acyl-piperazines as anti-viral agents
CN101484457B (zh) * 2006-04-12 2014-09-03 弗特克斯药品有限公司 作为用于治疗增殖病症的蛋白激酶PLK1抑制剂的4,5-二氢-[1,2,4]***并[4,3-f]蝶啶
JP5313875B2 (ja) * 2006-04-12 2013-10-09 バーテックス ファーマシューティカルズ インコーポレイテッド 増殖性疾患の処置のためのタンパク質キナーゼplk1の阻害剤として有用な4,5−ジヒドロ−[1,2,4]トリアゾロ[4,3−f]プテリジン
MX2009006345A (es) * 2006-12-14 2009-06-23 Vertex Pharma Compuestos utiles como inhibidores de proteina cinasa.
MX2010001677A (es) 2007-08-15 2010-03-11 Vertex Pharma Derivados de 4-(9-(3,3-difluorociclopentil)-5,7,7-trimetil-6-oxo-6 ,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-ilamino)-3-me toxibenzamida como inhibidores de las proteinas cinasas humanas plk1 a plk4 para el tratamiento de enfermedades proli
MX2011000026A (es) 2008-06-23 2011-02-24 Vertex Pharma Inhibidores de proteina cinasas.
MX2011000021A (es) 2008-06-23 2011-02-24 Vertex Pharma Inhibidores de proteina cinasas.
WO2010025073A1 (en) * 2008-08-28 2010-03-04 Takeda Pharmaceutical Company Limited Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors
WO2011079118A1 (en) * 2009-12-23 2011-06-30 Elan Pharmaceuticals, Inc Pteridinones as inhibitors of polo-like kinase

Also Published As

Publication number Publication date
US20120115848A1 (en) 2012-05-10
WO2012048129A3 (en) 2012-07-26
IL225605A0 (en) 2013-06-27
CA2814084A1 (en) 2012-04-12
CN103403010A (zh) 2013-11-20
WO2012048129A2 (en) 2012-04-12
AU2011311960A1 (en) 2014-04-10
RU2014118677A (ru) 2015-11-20
JP2013539759A (ja) 2013-10-28
EP2661268A2 (en) 2013-11-13

Similar Documents

Publication Publication Date Title
BR112013008526A2 (pt) inibidores de quinase do tipo polo
SMT201500271B (it) Inibitori di neprilisina
DK3178818T3 (da) Pyrazolylquinoxalinkinasehæmmere
DK2640893T4 (da) Sammensætninger
BR112012028556A2 (pt) Indóis
DE102011100241A8 (de) Nitridhalbleiterbauteil
CR20130111A (es) Triazina-oxidiazoles
DE10170954T8 (de) Mikrowellendruckgarer
DK2540728T3 (da) Heterocyklisk forbindelse
DK2596210T6 (da) Boring
DE102011117046A8 (de) Doppelkupplungswindungsgetriebe
DE112011100508A5 (de) Schulterstütze
FI20105772A0 (fi) Resonaattorisuodin
DE112011101333A5 (de) Parkouraufbau
BR112013003568A2 (pt) engate
DK2588615T3 (da) Selv-deleterende plasmid
DE102010019119B8 (de) Cuttermesser
DE112010005518A5 (de) Dichtungsmanchette
CO6801789A2 (es) N-hetarilmetil pirazolilcarboxamidas
DE102010035554B8 (de) Fußtüröffner
BR112013011455A2 (pt) microbiocidas
IT1401836B1 (it) Tesa portaocchiali
BR112013000109A2 (pt) composições
FI20105027A0 (fi) Höyrykattila
FR2957892B3 (fr) Trottinette amelioree

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.